Dabur India Limited (DABUR) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Dabur India, one of India's largest FMCG companies spanning health care, personal care, home care and foods with Ayurvedic and natural brands, heads into its September quarter print with management's own October 6 update pointing to double-digit consolidated revenue and PAT growth. The key tensions this quarter are the margin trajectory against elevated inflation in HPC and OTC & Ethicals, and the intensifying Middle East war that disrupts supply chains across the 30-35% of international business the region represents.

Dabur India Limited Q2 Results Date and Time

Per the September 22, 2026 board meeting intimation, Dabur India's board meets on November 4, 2026 to consider the Q2/H1 FY27 results along with interim dividend consideration.

No separate earnings call will be held for Q2 FY27. Instead, an in-person Analyst/Investor Meet is scheduled in Mumbai on November 5, 2026 at 4:00 p.m. IST, covering Q2 FY27 business performance, with no UPSI to be shared.

What to expect from Dabur India Limited's Q2 FY27 results

The quarter is framed by management's October 6 business update guiding to double-digit consolidated revenue and PAT growth, with India FMCG accelerating to double digits — its strongest performance in recent quarters — versus 9.5% growth on 5% volume in Q1 FY27.

Cost signals moved against the company through the quarter: Brent climbed from the mid-$70s-$80s in early July to above $100 by September 9 and held above $110 in late October, with crude-linked derivatives and packaging named as the September-quarter pressure points, and palm oil ~21% and sugar ~18% higher YoY in September.

Dabur has flagged elevated inflationary pressures, particularly in HPC and OTC & Ethicals, impacting operating margins, partly offset by calibrated price increases and cost-saving initiatives; Q1 FY27 consolidated OP margin stood at 19.7% against the erstwhile 20% operating margin target for FY27. On currency, the rupee traded a tight 95-96 band through the quarter versus 87.91 in mid-October 2025 — roughly 9% YoY depreciation — a translation tailwind on the international base that contributes about 27% of consolidated revenue.

The Middle East war remains the dominant overhang: the Middle East is 30-35% of the international business, with supply-chain disruption via Ras Al Khaimah, inflation and declining expat demand cited by management, and the double-digit profitable growth guidance stays conditional on the war situation per the Q1 call. The in-person analyst meet in Mumbai on November 5, 2026 will cover the Q2 FY27 business performance in detail.

Key Things To Watch

Double-digit revenue and PAT confirmation: The October 6 business update set a high bar for the September quarter.

• Double-digit consolidated revenue and PAT growth expected for Q2 FY27 per the Oct 6 update, against the FY27 double-digit consolidated guidance
• India FMCG expected to accelerate to double digits — its strongest in recent quarters — versus 9.5% in Q1 FY27
• Volume/price split against the guided ~50/50 FY27 framework, with the 2% price increase carried through into FY27

Margin trajectory vs the 20% operating margin target: Inflation in HPC and OTC & Ethicals was explicitly flagged as impacting operating margins in the Oct 6 update.

• Q1 FY27 consolidated OP margin was 19.7% (+10 bps YoY) against the erstwhile 20% operating margin target for FY27
• Watch whether the commitment to pass through 20-25% of gross-margin expansion as operating margin expansion is maintained
• Whether the margins-over-advertising stance held after A&P spend grew 13.6% in Q1 FY27

International growth and Middle East exposure: The Middle East is 30-35% of the international business and the war has intensified rather than ended.

• High-teens INR growth expected for International versus the FY27 double-digit international guidance, with a ~6% rupee-depreciation translation gain on top line
• MENA constant-currency trajectory after -5.4% cc growth in Q1 FY27, and route-cost commentary on Ras Al Khaimah disruption versus India, Egypt and Turkey alternatives
• Region momentum from Q1: Nigeria +35.1% INR, Bangladesh +34.3%, SSA +28.4%, Egypt +28.4%, Turkey +26.9%, UK +21.9%

Segment recovery and one-off items: Several segment-level and regulatory threads will draw attention on the call.

• HPC expected to post a fourth consecutive quarter of double-digit growth, with hair oils and shampoos in high-teens; OTC & Ethicals early-teens sequential recovery; F&B mid-teens versus the FY27 double-digit target
• Sesa Care amalgamation sanctioned by NCLT with appointed date April 1, 2026 — watch consolidation treatment and integration commentary
• US FDA Warning Letter (Silvassa plant; Import Alert 66-40 issued June 10, 2026) response status, and FSSAI '100%' labelling transition after the Delhi High Court stay of August 7, 2026

Growth ventures, rural momentum and pricing: Newer engines and the rural-urban split remain central to the FY27 growth mix.

• Siens tracking toward the Rs. 50 crores ARR target by year-end (FY27) and coconut water toward the Rs. 150 crores exit run-rate (ARR) target
• Rural demand outpaced urban by a 170 bps gap in Q1 FY27 (6.2% vs 4.6%); watch whether rural continues to outpace under Project Saksham
• Premiumisation at 17.0% of sales in FY26 with the premium portfolio growing 3x of core; Badshah scaled from Rs. 220 crores to Rs. 400 crores since acquisition